This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
All right, so I think we'll get started. Thanks everyone for joining us and I'm David Friedman, Biotech Analyst here. In terms of our disclosure statement, you can find research disclosures at morganstanley.com/researchdisclosures, and I am joined by Ron Barrett here, CEO of XenoPort, and one of the best performing stocks in all of small and midcap biotech this year, so a lot going on and I would to go into it, so maybe if you can just a one or two-minute overview of the company, and then we can just jump right into the program.
Sure. Thanks for the invitation to speak today and I am going to be making forward-looking statements and you should consult SEC documents with information with regard to risks and uncertainties of our business.
XenoPort, it's a very interesting time for the company. We have a series of products and product candidates that are in different stages and walk through them one at a time. Our gabapentin enacarbil is an approved product in the U.S. and Japan, and Horizant is the trade name in the U.S. and Regnite in Japan.
It's approved for the treatment of moderate-to-severe primary RLS in the U.S. and Japan, and also for postherpetic neuralgia in the U.S. we are partnered with GSK in the U.S. and Astellas in Japan, and I would say that I really don't have an update on Horizant's. It launched last July. The sales have been blockbuster and it's been very frustrating for us as a company, and as you undoubtedly know we are in litigations with GSK, I don't really have any update on the litigation today.